Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Surgery ; 2022 Aug 29.
Artículo en Inglés | MEDLINE | ID: covidwho-2239889

RESUMEN

BACKGROUND: The COVID-19 pandemic profoundly impacted the delivery of care and timing of elective surgical procedures. Most endocrine-related operations were considered elective and safe to postpone, providing a unique opportunity to assess clinical outcomes under protracted treatment plans. METHODS: American Association of Endocrine Surgeon members were surveyed for participation. A Research Electronic Data Capture survey was developed and distributed to 27 institutions to assess the impact of COVID-19-related delays. The information collected included patient demographics, primary diagnosis, resumption of care, and assessment of disease progression by the surgeon. RESULTS: Twelve out of 27 institutions completed the survey (44.4%). Of 850 patients, 74.8% (636) were female; median age was 56 (interquartile range, 44-66) years. Forty percent (34) of patients had not been seen since their original surgical appointment was delayed; 86.2% (733) of patients had a delay in care with women more likely to have a delay (87.6% vs 82.2% of men, χ2 = 3.84, P = .05). Median duration of delay was 70 (interquartile range, 42-118) days. Among patients with a delay in care, primary disease site included thyroid (54.2%), parathyroid (37.2%), adrenal (6.5%), and pancreatic/gastrointestinal neuroendocrine tumors (1.3%). In addition, 4.0% (26) of patients experienced disease progression and 4.1% (24) had a change from the initial operative plan. The duration of delay was not associated with disease progression (P = .96) or a change in operative plan (P = .66). CONCLUSION: Although some patients experienced disease progression during COVID-19 delays to endocrine disease-related care, most patients with follow-up did not. Our analysis indicated that temporary delay may be an acceptable course of action in extreme circumstances for most endocrine-related surgical disease.

2.
Endocr Pract ; 28(4): 405-413, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: covidwho-1616487

RESUMEN

OBJECTIVE: Cancer patients and survivors may be disproportionately affected by COVID-19. We sought to determine the effects of the pandemic on thyroid cancer survivors' health care interactions and quality of life. METHODS: An anonymous survey including questions about COVID-19 and the Patient-Reported Outcomes Measurement Information System profile (PROMIS-29, version 2.0) was hosted on the Thyroid Cancer Survivors' Association, Inc website. PROMIS scores were compared to previously published data. Factors associated with greater anxiety were evaluated with univariable and multivariable logistic regression. RESULTS: From May 6, 2020, to October 8, 2020, 413 participants consented to take the survey; 378 (92%) met the inclusion criteria: diagnosed with thyroid cancer or noninvasive follicular neoplasm with papillary-like nuclear features, located within the United States, and completed all sections of the survey. The mean age was 53 years, 89% were women, and 74% had papillary thyroid cancer. Most respondents agreed/strongly agreed (83%) that their lives were very different during the COVID-19 pandemic, as were their interactions with doctors (79%). A minority (43%) were satisfied with the information from their doctor regarding COVID-19 changes. Compared to pre-COVID-19, PROMIS scores were higher for anxiety (57.8 vs 56.5; P < .05) and lower for the ability to participate in social activities (46.2 vs 48.1; P < .01), fatigue (55.8 vs 57.9; P < .01), and sleep disturbance (54.7 vs 56.1; P < .01). After adjusting for confounders, higher anxiety was associated with younger age (P < .01) and change in treatment plan (P = .04). CONCLUSION: During the COVID-19 pandemic, thyroid cancer survivors reported increased anxiety compared to a pre-COVID cohort. To deliver comprehensive care, providers must better understand patient concerns and improve communication about potential changes to treatment plans.


Asunto(s)
COVID-19 , Supervivientes de Cáncer , Neoplasias de la Tiroides , Ansiedad/epidemiología , COVID-19/epidemiología , Femenino , Humanos , Internet , Persona de Mediana Edad , Pandemias , Calidad de Vida , Encuestas y Cuestionarios , Neoplasias de la Tiroides/epidemiología , Estados Unidos/epidemiología
3.
JAMA Cardiol ; 6(10): 1196-1201, 2021 10 01.
Artículo en Inglés | MEDLINE | ID: covidwho-1286092

RESUMEN

Importance: Vaccine-associated myocarditis is an unusual entity that has been described for the smallpox vaccine, but only anecdotal case reports have been described for other vaccines. Whether COVID-19 vaccination may be linked to the occurrence of myocarditis is unknown. Objective: To describe a group of 7 patients with acute myocarditis over 3 months, 4 of whom had recent messenger RNA (mRNA) COVID-19 vaccination. Design, Setting, and Participants: All patients referred for cardiovascular magnetic resonance imaging at Duke University Medical Center were asked to participate in a prospective outcomes registry. Two searches of the registry database were performed: first, to identify patients with acute myocarditis for the 3-month period between February 1 and April 30 for 2017 through 2021, and second, to identify all patients with possible vaccine-associated myocarditis for the past 20 years. Once patients with possible vaccine-associated myocarditis were identified, data available in the registry were supplemented by additional data collection from the electronic health record and a telephone interview. Exposures: mRNA COVID-19 vaccine. Main Outcomes and Measures: Occurrence of acute myocarditis by cardiovascular magnetic resonance imaging. Results: In the 3-month period between February 1 and April 30, 2021, 7 patients with acute myocarditis were identified, of which 4 occurred within 5 days of COVID-19 vaccination. Three were younger male individuals (age, 23-36 years) and 1 was a 70-year-old female individual. All 4 had received the second dose of an mRNA vaccine (2 received mRNA-1273 [Moderna], and 2 received BNT162b2 [Pfizer]). All presented with severe chest pain, had biomarker evidence of myocardial injury, and were hospitalized. Coincident testing for COVID-19 and respiratory viruses provided no alternative explanation. Cardiac magnetic resonance imaging findings were typical for myocarditis, including regional dysfunction, late gadolinium enhancement, and elevated native T1 and T2. Conclusions and Relevance: In this study, magnetic resonance imaging findings were found to be consistent with acute myocarditis in 7 patients; 4 of whom had preceding COVID-19 vaccination. Further investigation is needed to determine associations of COVID-19 vaccination and myocarditis.


Asunto(s)
Vacunas contra la COVID-19/efectos adversos , COVID-19/prevención & control , Miocarditis/etiología , Vacunación/estadística & datos numéricos , Vacuna nCoV-2019 mRNA-1273 , Enfermedad Aguda , Adulto , Anciano , Vacuna BNT162 , COVID-19/diagnóstico , COVID-19/epidemiología , COVID-19/virología , Vacunas contra la COVID-19/administración & dosificación , Técnicas de Imagen Cardíaca/métodos , Dolor en el Pecho/diagnóstico , Dolor en el Pecho/etiología , Femenino , Gadolinio/administración & dosificación , Gadolinio/metabolismo , Hospitalización , Humanos , Imagen por Resonancia Magnética/métodos , Masculino , Miocarditis/diagnóstico , Miocarditis/epidemiología , Evaluación de Resultado en la Atención de Salud , Estudios Prospectivos , Sistema de Registros , SARS-CoV-2/genética , Vacunación/métodos , Vacunación/tendencias
4.
Journal of the Endocrine Society ; 5(Supplement_1):A836-A836, 2021.
Artículo en Inglés | PMC | ID: covidwho-1221836

RESUMEN

Background: The coronavirus (COVID-19) pandemic has led to rapid changes in our society and healthcare system. Cancer patients and survivors may be disproportionately affected by these changes, including decreased access to healthcare, increased infection risk, and economic challenges. We sought to determine the effects of the pandemic on thyroid cancer survivors’ quality of life. Methods: An anonymous web-based survey was administered in collaboration with ThyCa: Thyroid Cancer Survivors’ Association, consisting of questions about (1) demographics, (2) thyroid cancer clinical characteristics, (3) attitudes toward and impact of COVID-19, and (4) the Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item profile. The survey was linked on the ThyCa homepage. PROMIS measures were scored using item response theory models with a T-score metric relative to U.S. reference data via the HealthMeasures Scoring Service (https://www.healthmeasures.net). T-scores were analyzed using Mann-Whitney U, Wilcoxon signed-rank, Kruskal-Wallis, and Spearman’s rank correlation tests. Results: From 5/6/2020 - 10/8/2020, 505 participants accessed the survey, and all completed surveys by U.S.-based thyroid cancer survivors were analyzed (n=378, 75%). Mean age was 53 years, 89% were female, 90% were white, 74% had papillary thyroid cancer, 97% had surgery, and 70% received radioactive iodine. The vast majority agreed or strongly agreed (83%) that their lives were very different during COVID-19, as was the way they interacted with their doctors (79%). Less than half (43%) agreed or strongly agreed that they were satisfied with the amount of information from their doctor’s office regarding COVID-19 changes. Compared to previously-published PROMIS data for this population, T-scores were significantly higher in the domain of anxiety/fear (57.8 vs. 56.5, p&lt;0.01) and lower for ability to participate in social roles and activities (46.2 vs. 48.1, p&lt;0.01). Younger age was weakly correlated with greater anxiety/fear (Spearman’s rho=-0.38, p&lt;0.01), and greater anxiety/fear was associated with pending treatment (p&lt;0.01), lower cancer stage (p=0.01), and female sex (p=0.02). Conclusions: During the COVID-19 pandemic, thyroid cancer survivors reported increased anxiety/fear and decreased social participation. In our efforts to care for patients both physically and mentally as the pandemic continues, we must better understand their fears and concerns and improve communication about potential changes to their care.

5.
Research Methods in Medicine & Health Sciences ; 2(1):31-38, 2020.
Artículo en Inglés | Sage | ID: covidwho-965841

RESUMEN

The UK Brexit debate and the current Covid pandemic have been fertile grounds for people seeking poor use of statistics, and demonstrate a need to reiterate some basic principles of data presentation. Communicating basic numbers to convey the correct message is a vital skill for a public health professional but even basic numbers can be difficult to understand, and are susceptible to misuse. The first issue is how to understand ?orphan? numbers;numbers quoted without comparison or context. This leads on to the problems of understand numbers as proportions and how to make comparisons using proportions. Percentages, and in particular percentage changes, are also a major source of misunderstanding and the baseline percentage should always be given. The use of relative risk can also convey the wrong message and should always be accompanied by a measure of absolute risk. Similarly, numbers needed to treat should also refer to baseline risks. Communicating numbers is often more effective using natural counts or frequencies rather than fractions or proportions, and using pictorial representations of proportions can also be effective. The paper will also examine the problems of using simple ratios to try and adjust one continuous variable by another in particular the use of the BMI and for standardising death rates by institution. The misuse of reporting occurs in primary sources such as academic papers, but even more so in secondary reporting sources such as general media reports. It is natural to try and convey complex messages using a single summary number, but there are assumptions behind these summaries that should be questioned. It is usually better to give the individual numbers rather than a ratio of them.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA